- Home
- LVLU vs MIRA Comparison
LVLU vs MIRA Comparison
Compare LVLU & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- MIRA
- Stock Information
- Founded
- LVLU 1996
- MIRA 2020
- Country
- LVLU United States
- MIRA United States
- Employees
- LVLU N/A
- MIRA N/A
- Industry
- LVLU Catalog/Specialty Distribution
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- MIRA Health Care
- Exchange
- LVLU Nasdaq
- MIRA Nasdaq
- Market Cap
- LVLU 18.4M
- MIRA 19.5M
- IPO Year
- LVLU 2021
- MIRA 2023
- Fundamental
- Price
- LVLU $0.38
- MIRA $1.22
- Analyst Decision
- LVLU Hold
- MIRA Strong Buy
- Analyst Count
- LVLU 2
- MIRA 2
- Target Price
- LVLU $1.00
- MIRA $14.00
- AVG Volume (30 Days)
- LVLU 95.5K
- MIRA 196.8K
- Earning Date
- LVLU 08-13-2025
- MIRA 08-12-2025
- Dividend Yield
- LVLU N/A
- MIRA N/A
- EPS Growth
- LVLU N/A
- MIRA N/A
- EPS
- LVLU N/A
- MIRA N/A
- Revenue
- LVLU $302,783,000.00
- MIRA N/A
- Revenue This Year
- LVLU N/A
- MIRA N/A
- Revenue Next Year
- LVLU $2.53
- MIRA N/A
- P/E Ratio
- LVLU N/A
- MIRA N/A
- Revenue Growth
- LVLU N/A
- MIRA N/A
- 52 Week Low
- LVLU $0.33
- MIRA $0.51
- 52 Week High
- LVLU $1.95
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- LVLU 41.91
- MIRA 46.38
- Support Level
- LVLU $0.44
- MIRA $1.19
- Resistance Level
- LVLU $0.56
- MIRA $1.34
- Average True Range (ATR)
- LVLU 0.06
- MIRA 0.09
- MACD
- LVLU -0.00
- MIRA -0.02
- Stochastic Oscillator
- LVLU 0.00
- MIRA 12.00
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.